IBD:吸烟与烟酰乙酰胆碱受体亚单位基因CHRNA5相互作用会影响IBD相关手术的风险

2018-05-20 MedSci MedSci原创

炎症性肠病(IBD)是一种慢性肠道疾病,伴有遗传和环境因素影响表型。本研究评估了烟酰胺受体亚单位基因CHRNA5与吸烟预测IBD相关手术之间的关系以及CHRNA5和尼古丁依赖之间的关系。

背景:
炎症性肠病IBD)是一种慢性肠道疾病,伴有遗传和环境因素影响表型。本研究评估了烟酰胺受体亚单位基因CHRNA5与吸烟预测IBD相关手术之间的关系以及CHRNA5和尼古丁依赖之间的关系。

方法:
所有参与者都完成了一份吸烟问卷,研究人员对所有患者的CHRNA5rs16969968进行了基因分型。人口统计学和临床数据来自数据库记录。Wilcoxon,ANOVA,Chi square和Fisher的精确测试用于比较。Logistic回归用于评估临床和遗传预测因子对手术的影响,按照吸烟的矛盾影响对疾病亚型进行分层。Kaplan-Meier曲线用于检查吸烟和基因型对手术的影响。(显着性:主效应P<0.05;P<0.2)

结果
400名(65.8%)患者患有克罗恩病(CD),208名患者(34.2%)患有溃疡性结肠炎(UC)。298名(49%)接受了IBD相关手术。rs16969968与吸烟行为呈显着性相关(吸烟状态P= 0.05,尼古丁依赖AA> AG> GG;P= 0.08)。吸烟和基因型与UC或CD手术无独立相关性。然而,对于UC(OR = 2.72;P= 0.05)和CD(OR = 2.88;P= 0.1),观察到rs16969968与吸烟在预测手术中的相互作用。CHRNA5基因型,预测UC患者接受手术的时间(P <0.05)= 0.007),但不适用于CD患者。在UC或CD中,吸烟与基因型之间的相互作用与手术时间没有显着关联。

结论
该CHRNA5rs16969968变化与吸烟的相互影响会增加IBD相关手术的风险。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载须授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-24 yfjms

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-22 121832a9m88暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-22 bnurmamat
  6. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-22 ylz8405
  7. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-22 grace5704
  8. [GetPortalCommentsPageByObjectIdResponse(id=1909242, encodeId=88891909242b7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Fri Feb 22 15:56:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085105, encodeId=4505208510535, content=<a href='/topic/show?id=3f91234e293' target=_blank style='color:#2F92EE;'>#乙酰胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23472, encryptionId=3f91234e293, topicName=乙酰胆碱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Sep 14 01:56:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318041, encodeId=fbd1318041c5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 24 06:31:31 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317350, encodeId=32ae31e350c1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Tue May 22 05:44:47 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263471, encodeId=eb6012634e18e, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471587, encodeId=687814e1587f1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527399, encodeId=5657152e399ae, content=<a href='/topic/show?id=10b483495a2' target=_blank style='color:#2F92EE;'>#胆碱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83495, encryptionId=10b483495a2, topicName=胆碱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce6211859522, createdName=grace5704, createdTime=Tue May 22 04:56:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317316, encodeId=a1f531e316a9, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/23/557c1f19aaf5459a8405411e38903c4b.jpg, createdBy=dfc02088287, createdName=cscdliu, createdTime=Mon May 21 22:47:25 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-21 cscdliu

    学习了.谢谢

    0

相关资讯

IBD:克罗恩病和溃疡性结肠炎肠道微生物会降低丁酸合成能力的因素

短链脂肪酸代谢的变化,特别是丁酸盐,已经在炎症性肠病中报道过,但是由于研究数量较少并且未能区分疾病类型,活性或其他变量,如饮食,所以结果相互矛盾。我们通过量化克罗恩病患者粪便中丁酰-CoA:乙酸CoA-转移酶BCoAT基因含量,对丁酸盐合成的微生物群的容量进行了比较评估。溃疡性结肠炎UC n = 58和对照组n= 75,并确定它是否与活性与非活性炎症,微生物多样性,组成和/或饮食习惯有关。

IBD: 荷尔蒙波动对炎症性肠病症状严重度的影响的横断面队列研究

许多炎症性肠病(IBD)妇女报告在月经,怀孕和使用激素避孕药期间与疾病症状的改变与体内激素变化相关。我们的目标是在激素变异期间鉴定女性IBD症状炎症活动程度的波动。

IBD:维多珠单抗作为炎症性肠病的诱导和维持的有效性和安全性研究

维多珠单抗(Vedolizumab)已经被批准用于中度至重度克罗恩病(CD)和溃疡性结肠炎(UC)。但是其在长期维持治疗中的作用还没有明确的文献报告,本项研究调查了使用维多珠单抗的患者12个月的疗效。

JCC:炎症性肠病患者的癌症风险与年龄和近期使用免疫调节剂有关,而生物制剂和氨基水杨酸盐是保护性因素。

癌症是炎症性肠病(IBD)患者的长期并发症之一。尽管免疫调节剂控制了肠道的慢性炎症,但可能会增加患癌的风险。我们的目的是以横断面和纵向的方式全面分析瑞士IBD队列(SIBDCS),以阐明癌症的发病率和发病率以及保护性和危险因素。

Am J Gastroenterology: 延长使用糖皮质激素相比于使用生物制剂对于IBD患者来说更具有生命危险。

克罗恩氏病(CD)和溃疡性结肠炎(UC)是炎症性肠病(IBD)的两种亚型,其损害生活质量并可能增加死亡率。本研究比较IBD患者长期使用皮质类固醇与抗肿瘤坏死因子-α(抗TNF)药物的死亡风险。

ALIMENT PHARM THERAP:早期维多珠单抗谷值水平预测炎症性肠病的粘膜愈合:一项多中心前瞻性观察性研究

本项研究旨在比较治疗开始后一年内有和没有粘膜愈合的患者的早期vedolizumab谷值水平。